World Health Organization (WHO)
Cinepazide, a vasodilating agent, was first introduced into
medicine in 1974. It is used in the treatment of peripheral and cerebral vascular
disorders. Following reports of blood dyscrasias, including agranulocytosis and
thrombocytopenia, associated with the use of the drug, the Spanish Committee on
Drug Surveillance has recommended its withdrawal. In other countries, the
approved product information of preparations containing cinepazide has been
amended to include a relevant warning on these adverse effects.
